Photo taken from ESMO/X
Jun 29, 2024, 03:18
Peter Schmid’s findings on atezolizumab and sacituzumab govitecan for advanced TNBC – ESMO
ESMO shared a post on LinkedIn:
“For ESMO members: Breaking Science in Breast Cancer.
Peter Schmid presents his findings on atezolizumab and sacituzumab govitecan for advanced Triple-negative breast cancer (TNBC).
Explore this video and others from this series on OncologyPRO now.”
Additional information
Source: ESMO/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 22, 2024, 10:18
Oct 22, 2024, 10:12
Oct 22, 2024, 09:38
Oct 22, 2024, 08:02
Oct 22, 2024, 07:20
Oct 22, 2024, 06:30
Oct 22, 2024, 06:13
Oct 22, 2024, 04:01
Oct 22, 2024, 03:40